<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352948</url>
  </required_header>
  <id_info>
    <org_study_id>D4191C00004</org_study_id>
    <nct_id>NCT02352948</nct_id>
  </id_info>
  <brief_title>A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer</brief_title>
  <acronym>ARCTIC</acronym>
  <official_title>A Phase III, Open Label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy
      and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with PD-L1
      positive tumours and the combination of MEDI4736 (durvalumab) plus tremelimumab
      (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the
      treatment of male and female patients with locally advanced or metastatic NSCLC (Stage
      IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1
      platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth
      factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase
      (ALK) rearrangements are not eligible for the study (prospective testing is not planned
      within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor
      (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has an umbrella design with 2 sub-studies: sub-study A (randomizing patients with
      PD-L1 positive tumours 1:1 into MEDI4736 (durvalumab) vs. Standard of Care) and sub-study B
      (randomizing patients with PD-L1 negative tumours 2:3:1:2 into MEDI4736 (durvalumab) vs.
      MEDI4736 (durvalumab) plus tremelimumab vs. tremelimumab vs. Standard of Care. The two
      substudies may have different durations of recruitment periods due to differences in patient
      population (PD-L1 expression). They may not run concurrently with start and completion of
      recruitment potentially occurring at different time points.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 13, 2015</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">February 9, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization (Day 1) until death due to any cause, approximately 36 months</time_frame>
    <description>The OS was defined as the time from the date of randomization until death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.</time_frame>
    <description>The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to response evaluation criteria in solid tumours (RECIST) version 1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS, Contribution of the Components Analysis of Sub-study B</measure>
    <time_frame>From randomization (Day 1) until death due to any cause, approximately 36 months</time_frame>
    <description>The OS was defined as the time from the date of randomization until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Alive at 12 Months (OS12)</measure>
    <time_frame>From randomization (Day 1) up to 12 months</time_frame>
    <description>The OS12 was defined as the percentage of participants who were alive at 12 months after randomisation per Kaplan-Meier estimate of OS at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS, Contribution of the Components Analysis of Sub-study B</measure>
    <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.</time_frame>
    <description>The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.</time_frame>
    <description>The ORR was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) among ITT participants who had measurable disease at baseline. CR was defined as disappearance of all target lesions (any pathological lymph nodes selected as target lesions must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum of diameters as long as criteria for PD are not met). The ORR was measured using Investigator assessments according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.</time_frame>
    <description>The DoR was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The DoR was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Alive and Progression Free at 6 Months (APF6)</measure>
    <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 6 months</time_frame>
    <description>The APF6 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 6 months after randomization per Kaplan-Meier estimate of PFS at 6 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Alive and Progression Free at 12 Months (APF12)</measure>
    <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 12 months.</time_frame>
    <description>The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 12 months after randomization per Kaplan-Meier estimate of PFS at 12 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomisation to Second Progression (PFS2) of Sub-study B</measure>
    <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until first progression. Disease then assessed per local practice until 2nd progression. Assessed up to a maximum of approximately 3 years.</time_frame>
    <description>The PFS2 was defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the PFS endpoint or death and determined by local standard clinical practice and have included any of the following: objective radiological, symptomatic progression, or death. PFS2 was reported for sub-study B only.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">597</enrollment>
  <condition>Non - Small Cell Lung Cancer NSCLC</condition>
  <arm_group>
    <arm_group_label>MEDI4736 (durvalumab) monotherapy in Sub-study A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care in Sub-study A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4736 (durvalumab) + tremelimumab in Sub-study B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care in Sub-study B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4736 (durvalumab) monotherapy in Sub-study B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tremelimumab in Sub-study B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI4736 (durvalumab)</intervention_name>
    <description>MEDI4736 (durvalumab) treatment by intravenous infusion</description>
    <arm_group_label>MEDI4736 (durvalumab) monotherapy in Sub-study A</arm_group_label>
    <arm_group_label>MEDI4736 (durvalumab) monotherapy in Sub-study B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.</description>
    <arm_group_label>Standard of Care in Sub-study A</arm_group_label>
    <arm_group_label>Standard of Care in Sub-study B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.</description>
    <arm_group_label>Standard of Care in Sub-study A</arm_group_label>
    <arm_group_label>Standard of Care in Sub-study B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration</description>
    <arm_group_label>Standard of Care in Sub-study A</arm_group_label>
    <arm_group_label>Standard of Care in Sub-study B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)</intervention_name>
    <description>MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion</description>
    <arm_group_label>MEDI4736 (durvalumab) + tremelimumab in Sub-study B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tremelimumab (anti-CTLA4)</intervention_name>
    <description>tremelimumab (anti-CTLA4) treatment by intravenous infusion</description>
    <arm_group_label>tremelimumab in Sub-study B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged at least 18 years

          -  Documented evidence of NSCLC (Stage IIIB/ IV disease)

          -  Disease progression or recurrence after both a platinum-based chemotherapy regimen and
             at least 1 additional regimen for treatment of NSCLC

          -  World Health Organization (WHO) Performance Status of 0 or 1

          -  Estimated life expectancy more than 12 weeks

        Exclusion Criteria:

          -  Prior exposure to any anti-PD-1 or anti-PD-L1 antibody or anti-CTLA4

          -  Brain metastases or spinal cord compression unless asymptomatic, treated and stable
             (not requiring steroids)

          -  Active or prior documented autoimmune disease within the past 2 years

          -  Evidence of severe or uncontrolled systemic disease, including active bleeding
             diatheses or active infections including hepatitis B, C and HIV

          -  Any unresolved toxicity CTCAE (Common Terminology Criteria of Adverse Events) &gt;Grade 2
             from previous anti-cancer therapy

          -  Known EGFR TK activating mutations or ALK rearrangements

          -  Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous
             immunotherapy agent, or any unresolved irAE &gt;Grade 1

          -  Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative
             colitis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Stockman, MBChB, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Battle Creek</city>
        <state>Michigan</state>
        <zip>49017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461-2375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208-1129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murdoch</city>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Macquarie</city>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Libramont-Chevigny</city>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1330</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>7500000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Temuco</city>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nova Ves pod Plesi</city>
        <zip>262 04</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Avignon Cedex 9</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier Cedex</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pau Cedex</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulon</city>
        <zip>83100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Löwenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54645</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Törökbálint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <zip>16100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lucca</city>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Habikino-shi</city>
        <zip>583-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hidaka-shi</city>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hirakata-shi</city>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hirosaki-shi</city>
        <zip>036-8545</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanazawa</city>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurume-shi</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsuyama-shi</city>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Natori-shi</city>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Okayama-shi</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osakasayama</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakai-shi</city>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <zip>980-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunto-gun</city>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takatsuki-shi</city>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wakayama-shi</city>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>204-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>236-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju-si</city>
        <zip>362-804</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jeonnam</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alba Iulia</city>
        <zip>510077</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baia Mare</city>
        <zip>430031</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400349</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400132</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Onesti</city>
        <zip>601048</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oradea</city>
        <zip>410469</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300210</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrad</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gornji Matejevac</city>
        <zip>18204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei City</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>116</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muang</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phitsanulok</city>
        <zip>65000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stevenage</city>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Czech Republic</country>
    <country>Philippines</country>
    <country>South Africa</country>
    <country>Turkey</country>
  </removed_countries>
  <link>
    <url>http://www.emergingmed.com/networks/AstraZeneca</url>
    <description>AstraZeneca Cancer Study Locator Service astrazeneca@emergingmed.com Phone number: 1-877-400-465</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2584&amp;filename=D4191C00004-sap-arctic-ed-3_Redacted.pdf</url>
    <description>Redacted SAP</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2584&amp;filename=D4191C00004-revised-csp-7_Redacted.pdf</url>
    <description>Redacted CSP</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 28, 2015</study_first_submitted>
  <study_first_submitted_qc>January 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <results_first_submitted>February 7, 2019</results_first_submitted>
  <results_first_submitted_qc>March 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02352948/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02352948/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was divided into 2 parts, sub-study A (82 centers across Europe, Asia, and North America) and sub-study B (149 centers across Europe, Asia, North America, and South America) conducted between 13 January 2015 and 09 February 2018 (data cut-off date).</recruitment_details>
      <pre_assignment_details>The study had a pre-screening period to determine the programmed cell death ligand 1 (PD-L1) status, followed by a screening period and 12 month treatment period. A total of 595 participants were randomized to either sub-study A [PD-L1 high (&gt;=25% of tumor cell (TC) expressing PD-L1)] or sub-study B [PD-L1 low/neg (&lt;25% of TC expressing PD-L1)].</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sub-study A: Durvalumab</title>
          <description>Participants received durvalumab (MEDI4736) 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks (Q2W) for 12 months (up to 26 doses).</description>
        </group>
        <group group_id="P2">
          <title>Sub-study A: Standard of Care (SoC)</title>
          <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/meter square (m^2) IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until progression of disease (PD), initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
        </group>
        <group group_id="P3">
          <title>Sub-study B: Durvalumab+Tremelimumab</title>
          <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion every 4 weeks (Q4W) for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
        </group>
        <group group_id="P4">
          <title>Sub-study B: SoC</title>
          <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
        </group>
        <group group_id="P5">
          <title>Sub-study B: Durvalumab</title>
          <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
        </group>
        <group group_id="P6">
          <title>Sub-study B: Tremelimumab</title>
          <description>Participants received tremelimumab 10 mg/kg IV infusion Q4W for 24 weeks followed by every 12 weeks (Q12W) for 24 weeks (up to 9 doses).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="174"/>
                <participants group_id="P4" count="118"/>
                <participants group_id="P5" count="117"/>
                <participants group_id="P6" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="173"/>
                <participants group_id="P4" count="110"/>
                <participants group_id="P5" count="117"/>
                <participants group_id="P6" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="29"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="129"/>
                <participants group_id="P4" count="99"/>
                <participants group_id="P5" count="88"/>
                <participants group_id="P6" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="114"/>
                <participants group_id="P4" count="74"/>
                <participants group_id="P5" count="77"/>
                <participants group_id="P6" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Sub-study A and B: Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
      <group_list>
        <group group_id="B1">
          <title>Sub-study A: Durvalumab</title>
          <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
        </group>
        <group group_id="B2">
          <title>Sub-study A: SoC</title>
          <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
        </group>
        <group group_id="B3">
          <title>Sub-study B: Durvalumab+Tremelimumab</title>
          <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion Q4W for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
        </group>
        <group group_id="B4">
          <title>Sub-study B: SoC</title>
          <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
        </group>
        <group group_id="B5">
          <title>Sub-study B: Durvalumab</title>
          <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
        </group>
        <group group_id="B6">
          <title>Sub-study B: Tremelimumab</title>
          <description>Participants received tremelimumab 10 mg/kg IV infusion Q4W for 24 weeks followed by Q12W for 24 weeks (up to 9 doses).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="174"/>
            <count group_id="B4" value="118"/>
            <count group_id="B5" value="117"/>
            <count group_id="B6" value="60"/>
            <count group_id="B7" value="595"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;50 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=50 to &lt;65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="263"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 to &lt;75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="222"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="73"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="79"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="405"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>The OS was defined as the time from the date of randomization until death due to any cause.</description>
        <time_frame>From randomization (Day 1) until death due to any cause, approximately 36 months</time_frame>
        <population>Sub-study A and B: FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-study A: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O2">
            <title>Sub-study A: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O3">
            <title>Sub-study B: Durvalumab+Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion Q4W for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
          </group>
          <group group_id="O4">
            <title>Sub-study B: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>The OS was defined as the time from the date of randomization until death due to any cause.</description>
          <population>Sub-study A and B: FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="174"/>
                <count group_id="O4" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="8.2" upper_limit="17.4"/>
                    <measurement group_id="O2" value="6.8" lower_limit="4.9" upper_limit="10.2"/>
                    <measurement group_id="O3" value="11.5" lower_limit="8.7" upper_limit="14.1"/>
                    <measurement group_id="O4" value="8.7" lower_limit="6.5" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For sub-study A: durvalumab monotherapy treatment arm was compared with SoC.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Sub-study A was not powered and thus no formal statistical comparisons were performed.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For sub-study B: durvalumab plus tremelimumab treatment arm was compared with SoC.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>Log Rank</method>
            <method_desc>The P-value arises from a stratified log-rank test adjusting for SoC therapy and histology, with ties handled by the Breslow approach.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to response evaluation criteria in solid tumours (RECIST) version 1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
        <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.</time_frame>
        <population>Sub-study A and B: FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-study A: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O2">
            <title>Sub-study A: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O3">
            <title>Sub-study B: Durvalumab+Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion Q4W for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
          </group>
          <group group_id="O4">
            <title>Sub-study B: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to response evaluation criteria in solid tumours (RECIST) version 1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
          <population>Sub-study A and B: FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="174"/>
                <count group_id="O4" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="1.9" upper_limit="5.6"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.9" upper_limit="3.7"/>
                    <measurement group_id="O3" value="3.5" lower_limit="2.3" upper_limit="4.6"/>
                    <measurement group_id="O4" value="3.5" lower_limit="1.9" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For sub-study A: durvalumab monotherapy treatment arm was compared with SoC.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Sub-study A was not powered and thus no formal statistical comparisons were performed.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For sub-study B: durvalumab plus tremelimumab treatment arm was compared with SoC.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>Log Rank</method>
            <method_desc>The P-value arises from a stratified log-rank test adjusting for SoC therapy and histology, with ties handled by the Breslow approach.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS, Contribution of the Components Analysis of Sub-study B</title>
        <description>The OS was defined as the time from the date of randomization until death due to any cause.</description>
        <time_frame>From randomization (Day 1) until death due to any cause, approximately 36 months</time_frame>
        <population>FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-study B: Durvalumab+Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion Q4W for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
          </group>
          <group group_id="O2">
            <title>Sub-study B: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O3">
            <title>Sub-study B: Tremelimumab</title>
            <description>Participants received tremelimumab 10 mg/kg IV infusion Q4W for 24 weeks followed by Q12W for 24 weeks (up to 9 doses).</description>
          </group>
        </group_list>
        <measure>
          <title>OS, Contribution of the Components Analysis of Sub-study B</title>
          <description>The OS was defined as the time from the date of randomization until death due to any cause.</description>
          <population>FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="8.7" upper_limit="14.1"/>
                    <measurement group_id="O2" value="10.0" lower_limit="7.1" upper_limit="13.2"/>
                    <measurement group_id="O3" value="6.9" lower_limit="3.9" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>As part of the contribution of components analysis for sub-study B, durvalumab plus tremelimumab treatment arm was compared with durvalumab monotherapy.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.885</p_value>
            <method>Log Rank</method>
            <method_desc>The P-value arises from a stratified log-rank test adjusting for SoC therapy and histology, with ties handled by the Breslow approach.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As part of the contribution of components analysis for sub-study B, durvalumab plus tremelimumab treatment arm was compared with tremelimumab monotherapy.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.153</p_value>
            <method>Log Rank</method>
            <method_desc>The P-value arises from a stratified log-rank test adjusting for SoC therapy and histology, with ties handled by the Breslow approach.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Alive at 12 Months (OS12)</title>
        <description>The OS12 was defined as the percentage of participants who were alive at 12 months after randomisation per Kaplan-Meier estimate of OS at 12 months.</description>
        <time_frame>From randomization (Day 1) up to 12 months</time_frame>
        <population>Sub-study A and B: FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-study A: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O2">
            <title>Sub-study A: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O3">
            <title>Sub-study B: Durvalumab+Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion Q4W for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
          </group>
          <group group_id="O4">
            <title>Sub-study B: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O5">
            <title>Sub-study B: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O6">
            <title>Sub-study B: Tremelimumab</title>
            <description>Participants received tremelimumab 10 mg/kg IV infusion Q4W for 24 weeks followed by Q12W for 24 weeks (up to 9 doses).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Alive at 12 Months (OS12)</title>
          <description>The OS12 was defined as the percentage of participants who were alive at 12 months after randomisation per Kaplan-Meier estimate of OS at 12 months.</description>
          <population>Sub-study A and B: FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="174"/>
                <count group_id="O4" value="118"/>
                <count group_id="O5" value="117"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" lower_limit="36.3" upper_limit="61.0"/>
                    <measurement group_id="O2" value="31.3" lower_limit="20.2" upper_limit="43.0"/>
                    <measurement group_id="O3" value="49.5" lower_limit="41.7" upper_limit="56.7"/>
                    <measurement group_id="O4" value="38.8" lower_limit="29.9" upper_limit="47.7"/>
                    <measurement group_id="O5" value="43.6" lower_limit="34.4" upper_limit="52.4"/>
                    <measurement group_id="O6" value="41.2" lower_limit="28.7" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For sub-study B: durvalumab plus tremelimumab treatment arm was compared with SoC.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.063</p_value>
            <p_value_desc>The z-test statistic is the ratio of log-transformed ratio of the cumulative hazards in the 2 treatment arms divided by square root of the variance.</p_value_desc>
            <method>z-test</method>
            <method_desc>The variance is estimated using the delta method and Greenwood's formula.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS, Contribution of the Components Analysis of Sub-study B</title>
        <description>The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
        <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.</time_frame>
        <population>FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-study B: Durvalumab+Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion Q4W for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
          </group>
          <group group_id="O2">
            <title>Sub-study B: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O3">
            <title>Sub-study B: Tremelimumab</title>
            <description>Participants received tremelimumab 10 mg/kg IV infusion Q4W for 24 weeks followed by Q12W for 24 weeks (up to 9 doses).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS, Contribution of the Components Analysis of Sub-study B</title>
          <description>The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
          <population>FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.3" upper_limit="4.6"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.9" upper_limit="3.7"/>
                    <measurement group_id="O3" value="2.1" lower_limit="1.8" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>As part of the contribution of components analysis for sub-study B, durvalumab plus tremelimumab treatment arm was compared with durvalumab monotherapy.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.282</p_value>
            <method>Log Rank</method>
            <method_desc>The P-value arises from a stratified log-rank test adjusting for SoC therapy and histology, with ties handled by the Breslow approach.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As part of the contribution of components analysis for sub-study B, durvalumab plus tremelimumab treatment arm was compared with tremelimumab monotherapy.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Log Rank</method>
            <method_desc>The P-value arises from a stratified log-rank test adjusting for SoC therapy and histology, with ties handled by the Breslow approach.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>The ORR was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) among ITT participants who had measurable disease at baseline. CR was defined as disappearance of all target lesions (any pathological lymph nodes selected as target lesions must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum of diameters as long as criteria for PD are not met). The ORR was measured using Investigator assessments according to RECIST v1.1.</description>
        <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.</time_frame>
        <population>Sub-study A and B: FAS included all randomized participants with measureable disease at baseline analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-study A: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O2">
            <title>Sub-study A: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O3">
            <title>Sub-study B: Durvalumab+Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion Q4W for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
          </group>
          <group group_id="O4">
            <title>Sub-study B: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O5">
            <title>Sub-study B: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O6">
            <title>Sub-study B: Tremelimumab</title>
            <description>Participants received tremelimumab 10 mg/kg IV infusion Q4W for 24 weeks followed by Q12W for 24 weeks (up to 9 doses).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>The ORR was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) among ITT participants who had measurable disease at baseline. CR was defined as disappearance of all target lesions (any pathological lymph nodes selected as target lesions must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum of diameters as long as criteria for PD are not met). The ORR was measured using Investigator assessments according to RECIST v1.1.</description>
          <population>Sub-study A and B: FAS included all randomized participants with measureable disease at baseline analyzed on an ITT basis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="174"/>
                <count group_id="O4" value="118"/>
                <count group_id="O5" value="117"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="14.9"/>
                    <measurement group_id="O4" value="6.8"/>
                    <measurement group_id="O5" value="15.4"/>
                    <measurement group_id="O6" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For sub-study A: durvalumab monotherapy treatment arm was compared with SoC.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Sub-study A was not powered and thus no formal statistical comparisons were performed.</non_inferiority_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.61</ci_lower_limit>
            <ci_upper_limit>10.10</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for SoC therapy (gemcitabine/vinorelbine versus erlotinib) and histology (squamous versus all other histology types), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For sub-study B: durvalumab plus tremelimumab treatment arm was compared with SoC.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>5.94</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for SoC therapy (gemcitabine/vinorelbine versus erlotinib) and histology (squamous versus all other histology types), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>For sub-study B: durvalumab plus tremelimumab treatment arm was compared with durvalumab monotherapy.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.923</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for SoC therapy (gemcitabine/vinorelbine versus erlotinib) and histology (squamous versus all other histology types), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For sub-study B: durvalumab plus tremelimumab treatment arm was compared with tremelimumab monotherapy.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>8.61</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for SoC therapy (gemcitabine/vinorelbine versus erlotinib) and histology (squamous versus all other histology types), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR)</title>
        <description>The DoR was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The DoR was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
        <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.</time_frame>
        <population>Sub-study A and B: FAS included all randomized participants with measureable disease at baseline analyzed on an ITT basis. Only participants with objective response were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-study A: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O2">
            <title>Sub-study A: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O3">
            <title>Sub-study B: Durvalumab+Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion Q4W for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
          </group>
          <group group_id="O4">
            <title>Sub-study B: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O5">
            <title>Sub-study B: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O6">
            <title>Sub-study B: Tremelimumab</title>
            <description>Participants received tremelimumab 10 mg/kg IV infusion Q4W for 24 weeks followed by Q12W for 24 weeks (up to 9 doses).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR)</title>
          <description>The DoR was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The DoR was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
          <population>Sub-study A and B: FAS included all randomized participants with measureable disease at baseline analyzed on an ITT basis. Only participants with objective response were analyzed.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="174"/>
                <count group_id="O4" value="118"/>
                <count group_id="O5" value="117"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="3.0" upper_limit="17.8"/>
                    <measurement group_id="O2" value="4.8" lower_limit="1.9" upper_limit="7.6"/>
                    <measurement group_id="O3" value="12.2" lower_limit="6.5" upper_limit="NA">The upper limit of the 75th percentile was not calculated as it was not reached.</measurement>
                    <measurement group_id="O4" value="10.8" lower_limit="5.6" upper_limit="12.2"/>
                    <measurement group_id="O5" value="10.0" lower_limit="4.0" upper_limit="NA">The upper limit of the 75th percentile was not calculated as it was not reached.</measurement>
                    <measurement group_id="O6" value="4.7" lower_limit="2.9" upper_limit="NA">The upper limit of the 75th percentile was not calculated as it was not reached.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Alive and Progression Free at 6 Months (APF6)</title>
        <description>The APF6 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 6 months after randomization per Kaplan-Meier estimate of PFS at 6 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
        <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 6 months</time_frame>
        <population>Sub-study A and B: FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-study A: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O2">
            <title>Sub-study A: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O3">
            <title>Sub-study B: Durvalumab+Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion Q4W for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
          </group>
          <group group_id="O4">
            <title>Sub-study B: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O5">
            <title>Sub-study B: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O6">
            <title>Sub-study B: Tremelimumab</title>
            <description>Participants received tremelimumab 10 mg/kg IV infusion Q4W for 24 weeks followed by Q12W for 24 weeks (up to 9 doses).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Alive and Progression Free at 6 Months (APF6)</title>
          <description>The APF6 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 6 months after randomization per Kaplan-Meier estimate of PFS at 6 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
          <population>Sub-study A and B: FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="174"/>
                <count group_id="O4" value="118"/>
                <count group_id="O5" value="117"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="23.9" upper_limit="47.3"/>
                    <measurement group_id="O2" value="24.1" lower_limit="14.1" upper_limit="35.6"/>
                    <measurement group_id="O3" value="31.5" lower_limit="24.6" upper_limit="38.7"/>
                    <measurement group_id="O4" value="27.6" lower_limit="19.0" upper_limit="36.7"/>
                    <measurement group_id="O5" value="27.2" lower_limit="19.4" upper_limit="35.6"/>
                    <measurement group_id="O6" value="14.5" lower_limit="6.9" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Alive and Progression Free at 12 Months (APF12)</title>
        <description>The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 12 months after randomization per Kaplan-Meier estimate of PFS at 12 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
        <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 12 months.</time_frame>
        <population>Sub-study A and B: FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-study A: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O2">
            <title>Sub-study A: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O3">
            <title>Sub-study B: Durvalumab+Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion Q4W for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
          </group>
          <group group_id="O4">
            <title>Sub-study B: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O5">
            <title>Sub-study B: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O6">
            <title>Sub-study B: Tremelimumab</title>
            <description>Participants received tremelimumab 10 mg/kg IV infusion Q4W for 24 weeks followed by Q12W for 24 weeks (up to 9 doses).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Alive and Progression Free at 12 Months (APF12)</title>
          <description>The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 12 months after randomization per Kaplan-Meier estimate of PFS at 12 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion</description>
          <population>Sub-study A and B: FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="174"/>
                <count group_id="O4" value="118"/>
                <count group_id="O5" value="117"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" lower_limit="10.7" upper_limit="30.0"/>
                    <measurement group_id="O2" value="9.9" lower_limit="3.8" upper_limit="19.3"/>
                    <measurement group_id="O3" value="20.6" lower_limit="14.7" upper_limit="27.1"/>
                    <measurement group_id="O4" value="8.0" lower_limit="3.4" upper_limit="15.2"/>
                    <measurement group_id="O5" value="15.0" lower_limit="9.1" upper_limit="22.3"/>
                    <measurement group_id="O6" value="7.3" lower_limit="2.4" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomisation to Second Progression (PFS2) of Sub-study B</title>
        <description>The PFS2 was defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the PFS endpoint or death and determined by local standard clinical practice and have included any of the following: objective radiological, symptomatic progression, or death. PFS2 was reported for sub-study B only.</description>
        <time_frame>Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until first progression. Disease then assessed per local practice until 2nd progression. Assessed up to a maximum of approximately 3 years.</time_frame>
        <population>FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sub-study B: Durvalumab+Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion Q4W for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
          </group>
          <group group_id="O2">
            <title>Sub-study B: SoC</title>
            <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anti-cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
          </group>
          <group group_id="O3">
            <title>Sub-study B: Durvalumab</title>
            <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
          </group>
          <group group_id="O4">
            <title>Sub-study B: Tremelimumab</title>
            <description>Participants received tremelimumab 10 mg/kg IV infusion Q4W for 24 weeks followed by Q12W for 24 weeks (up to 9 doses).</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomisation to Second Progression (PFS2) of Sub-study B</title>
          <description>The PFS2 was defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the PFS endpoint or death and determined by local standard clinical practice and have included any of the following: objective radiological, symptomatic progression, or death. PFS2 was reported for sub-study B only.</description>
          <population>FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="6.6" upper_limit="12.3"/>
                    <measurement group_id="O2" value="6.7" lower_limit="4.7" upper_limit="8.9"/>
                    <measurement group_id="O3" value="8.0" lower_limit="6.3" upper_limit="10.0"/>
                    <measurement group_id="O4" value="5.7" lower_limit="3.2" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For sub-study B: durvalumab plus tremelimumab treatment arm was compared with SoC.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Log Rank</method>
            <method_desc>The P-value arises from a stratified log-rank test adjusting for SoC therapy and histology, with ties handled by the Breslow approach.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>Hazard ratio and CI are estimated from a stratified Cox proportional hazards model with Breslow method to control for ties, stratification factors SoC therapy, and histology in strata statement, and CI is calculated using profile likelihood approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signature of informed consent up to 90 days after the last dose of durvalumab and/or tremelimumab and 30 days after the last dose of SoC, approximately 15 months.</time_frame>
      <desc>Sub-study A and B: Safety analysis set included all participants who received at least 1 dose of randomized treatment. All-cause mortality is defined as death due to any cause (including disease progression) for the entire duration of the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sub-study A: Durvalumab</title>
          <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
        </group>
        <group group_id="E2">
          <title>Sub-study A: SoC</title>
          <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
        </group>
        <group group_id="E3">
          <title>Sub-study B: Durvalumab+Tremelimumab</title>
          <description>Participants received durvalumab 20 mg/kg plus tremelimumab 1 mg/kg IV infusion Q4W for 12 weeks (4 doses) followed by durvalumab alone 10 mg/kg IV infusion Q2W for 34 weeks starting at Week 16 (up to 18 additional doses).</description>
        </group>
        <group group_id="E4">
          <title>Sub-study B: SoC</title>
          <description>Participants received either erlotinib 150 mg tablet orally once daily; gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle; or vinorelbine 30 mg/m^2 IV infusion on Days 1, 8, 15, and 22 of a 28-day cycle until PD, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment criterion occurred.</description>
        </group>
        <group group_id="E5">
          <title>Sub-study B: Durvalumab</title>
          <description>Participants received durvalumab 10 mg/kg IV infusion Q2W for 12 months (up to 26 doses).</description>
        </group>
        <group group_id="E6">
          <title>Sub-study B: Tremelimumab</title>
          <description>Participants received tremelimumab 10 mg/kg IV infusion Q4W for 24 weeks followed by Q12W for 24 weeks (up to 9 doses).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="174"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="83" subjects_at_risk="117"/>
                <counts group_id="E6" subjects_affected="46" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="173"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="110"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="117"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Glucocorticoid deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lymphangiosis carcinomatosa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tumour necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bronchial fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Internal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="139" subjects_at_risk="173"/>
                <counts group_id="E4" subjects_affected="100" subjects_at_risk="110"/>
                <counts group_id="E5" subjects_affected="99" subjects_at_risk="117"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="63"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="173"/>
                <counts group_id="E4" events="49" subjects_affected="27" subjects_at_risk="110"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="117"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E4" events="15" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="40" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E4" events="48" subjects_affected="18" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E4" events="15" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="117"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="62"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="173"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E5" events="16" subjects_affected="15" subjects_at_risk="117"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E3" events="45" subjects_affected="36" subjects_at_risk="173"/>
                <counts group_id="E4" events="26" subjects_affected="18" subjects_at_risk="110"/>
                <counts group_id="E5" events="33" subjects_affected="25" subjects_at_risk="117"/>
                <counts group_id="E6" events="20" subjects_affected="16" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="62"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E3" events="33" subjects_affected="28" subjects_at_risk="173"/>
                <counts group_id="E4" events="32" subjects_affected="22" subjects_at_risk="110"/>
                <counts group_id="E5" events="25" subjects_affected="20" subjects_at_risk="117"/>
                <counts group_id="E6" events="16" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="173"/>
                <counts group_id="E4" events="13" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E5" events="22" subjects_affected="18" subjects_at_risk="117"/>
                <counts group_id="E6" events="10" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="17" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E3" events="39" subjects_affected="31" subjects_at_risk="173"/>
                <counts group_id="E4" events="19" subjects_affected="17" subjects_at_risk="110"/>
                <counts group_id="E5" events="21" subjects_affected="16" subjects_at_risk="117"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="62"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E3" events="27" subjects_affected="25" subjects_at_risk="173"/>
                <counts group_id="E4" events="30" subjects_affected="24" subjects_at_risk="110"/>
                <counts group_id="E5" events="24" subjects_affected="22" subjects_at_risk="117"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="173"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E3" events="27" subjects_affected="20" subjects_at_risk="173"/>
                <counts group_id="E4" events="33" subjects_affected="23" subjects_at_risk="110"/>
                <counts group_id="E5" events="15" subjects_affected="12" subjects_at_risk="117"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="173"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E4" events="15" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E5" events="9" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E5" events="5" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="33" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E4" events="43" subjects_affected="18" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="27" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="173"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="21" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E4" events="32" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="62"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="63"/>
                <counts group_id="E3" events="39" subjects_affected="34" subjects_at_risk="173"/>
                <counts group_id="E4" events="24" subjects_affected="23" subjects_at_risk="110"/>
                <counts group_id="E5" events="28" subjects_affected="27" subjects_at_risk="117"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="173"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="117"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E5" events="15" subjects_affected="14" subjects_at_risk="117"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E5" events="11" subjects_affected="9" subjects_at_risk="117"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="173"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="62"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E3" events="26" subjects_affected="25" subjects_at_risk="173"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="110"/>
                <counts group_id="E5" events="17" subjects_affected="16" subjects_at_risk="117"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E3" events="29" subjects_affected="24" subjects_at_risk="173"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="110"/>
                <counts group_id="E5" events="20" subjects_affected="15" subjects_at_risk="117"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E3" events="11" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="36" subjects_affected="28" subjects_at_risk="173"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="117"/>
                <counts group_id="E6" events="17" subjects_affected="14" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="173"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="110"/>
                <counts group_id="E5" events="9" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E6" events="11" subjects_affected="9" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Science Director</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+1 302 885 1180</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

